Martínez, Patricia Torres
García, Paula Diaque
Salas, María Rubio
Sánchez, Raquel Rodríguez
Avendaño-Ortíz, José
Guerrero-Monjo, Sandra
García, Felipe
Llamas, Miguel Ángel
López-Collazo, Eduardo
Saz-Leal, Paula
del Fresno, Carlos
Funding for this research was provided by:
Instituto de Salud Carlos III (Miguel Servet Program CP20/00106)
Article History
Received: 16 August 2020
Accepted: 21 October 2021
First Online: 3 November 2021
Competing interests
: M.A.LL, F.G and C.delF. are founders, board members and shareholders of EMPIREO Diagnóstico Molecular. E.L.-C. is founder and shareholder of EMPIREO Diagnóstico Molecular. P.T.M, was and P.D.G., M.R.S., S.G-M and R.R.S. are employees of EMPIREO Diagnóstico Molecular. J.A-O and P.S-L. do not declare potential competing interests.